股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 卓珈控股集團有限公司 (「本公司」)(於開曼群島註冊成立之有限公司) 呈交日期: 2025年11月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01827 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 2,000,000,000 | HKD | | 0.01 HKD | | 20,000,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | 本月底結存 | | | 2,000,000,000 | HKD | | 0.01 HKD | | 20,000,000 | 本月 ...

截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 卓珈控股集團有限公司 (「本公司」)(於開曼群島註冊成立之有限公司) 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 FF301 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01827 | 說明 | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 400,000,000 | | | | 400,000,000 | | 增加 / 減少 (-) | | | 0 | | | | | | 本月底結存 | | | 400,000,000 | | 0 | | 400,000,000 | 第 2 頁 共 10 頁 v 1.1.1 第 1 頁 共 10 頁 v 1.1.1 FF301 呈交日期: 2025年10月 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部 分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 Miricor Enterprises Holdings Limited 卓珈控股集團有限公司 （於開曼群島註冊成立的有限公司） （股份代號：1827） 2025年9月29日舉行之 股東週年大會投票表決結果 茲提述卓珈控股集團有限公司（「本公司」）日期為2025年7月25日的股東週年大會通 告、本公司日期為2025年7月25日的通函及本公司日期為2025年9月22日之公告。 本公司欣然宣佈於2025年9月29日舉行之本公司股東週年大會（「股東週年大會」）上 提呈之決議案的投票表決結果如下： | | 普通決議案 | | 票數(%) | | | --- | --- | --- | --- | --- | | | | | 贊成 反對 | | | 1. | | 省覽及考慮截至2025年3月31日止年度之經審核 320,130,000 | | 0 | | | | (100%) 綜合財務報表及董事會報告及獨立核數師報 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部 分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 Miricor Enterprises Holdings Limited 卓珈控股集團有限公司 （於開曼群島註冊成立的有限公司） （股份代號：1827） 由於颱風原定於2025年9月23日舉行的股東週年大會將延期 茲提述卓珈控股集團有限公司（「本公司」）日期為2025年7月25日的股東週年大會 （「股東週年大會」）通告（「股東週年大會通告」）及本公司日期為2025年7月25日的通 函（「該通函」）。除另有界定者外，本公告所用詞彙與該通函所界定者具有相同涵義。 為釐定股東出席股東週年大會並於會上投票之資格而暫停辦理股份過戶登記手續 的期間（如該通函所述）將維持不變。就股東週年大會而言，寄存於本公司的香港股 份過戶登記分處卓佳證券登記有限公司的所有代表委任表格將於經改期之股東週 年大會上維持有效。 承董事會命 卓珈控股集團有限公司 主席兼行政總裁 黎珈而 香港，2025年9月22日 於本公告日期，董事會包括三 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 卓珈控股集團有限公司 (「本公司」)(於開曼群島註冊成立之有限公司) 呈交日期: 2025年9月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01827 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 2,000,000,000 | HKD | | 0.01 HKD | | 20,000,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | 本月底結存 | | | 2,000,000,000 | HKD | | 0.01 HKD | | 20,000,000 | 本月底法 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 卓珈控股集團有限公司 (「本公司」)(於開曼群島註冊成立之有限公司) 呈交日期: 2025年8月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01827 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 2,000,000,000 | HKD | | 0.01 HKD | | 20,000,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | 本月底結存 | | | 2,000,000,000 | HKD | | 0.01 HKD | | 20,000,000 | 本月底法 ...

Financial Performance - The Group achieved a revenue of HK$403.2 million for FY2025, a decrease of 18.4% compared to HK$494.3 million in FY2024[11]. - Earnings before interest, taxes, and depreciation for FY2025 was HK$58.6 million, representing an increase of 84.9% year-on-year from HK$31.7 million in FY2024[11]. - The Group reported a net profit of HK$10.6 million for FY2025, a turnaround from a net loss of HK$12.6 million in FY2024[11]. - The Group's revenue for FY2025 was approximately HK$403.2 million, a decrease of about HK$91.1 million or 18.4% compared to HK$494.3 million in FY2024[66]. - Revenue from treatment services amounted to approximately HK$350.3 million in FY2025, representing 86.9% of total revenue, down by approximately HK$24.2 million or 6.5% from FY2024[69]. - Revenue from skincare products decreased to approximately HK$52.8 million in FY2025, representing 13.1% of total revenue, a decline of approximately HK$66.8 million or 55.9% from FY2024[71]. - Other income and gain, net increased to approximately HK$6.4 million in FY2025, up by approximately HK$0.6 million or 10.3% from FY2024[76]. Cost Management - Operating expenses were reduced by 24.5% year-on-year through supply chain optimisation and other measures[26]. - Operating expenses decreased by 24.5% year-on-year, significantly lowering the expense-to-revenue ratio[28]. - Staff costs decreased by approximately HK$42.2 million or 23.0%, from approximately HK$183.8 million in FY2024 to approximately HK$141.6 million in FY2025[78]. - Property rentals and related expenses decreased by approximately HK$13.7 million or 20.2%, from approximately HK$67.9 million in FY2024 to approximately HK$54.2 million in FY2025[79]. - Other expenses, net decreased by approximately HK$59.5 million from approximately HK$159.6 million in FY2024 to HK$100.1 million in FY2025, a reduction of 37.3%[87]. Market Trends - The medical aesthetic and wellness beauty market in Hong Kong is expected to grow steadily, driven by rising demand for personalised services[20]. - The medical aesthetics market in Hong Kong is experiencing steady growth, driven by increased consumer demand and technological advancements[34]. - Non-surgical aesthetic services are dominating the market, particularly Botox and hyaluronic acid injections, due to their less invasive nature[36]. - The consumer base is becoming younger, with the 20-40 age group now representing the majority of medical aesthetics consumers[36]. - Skincare retail revenue faced a temporary adjustment due to subdued retail market conditions and consumer sentiment[65]. Customer Engagement - Customer satisfaction and customer bases continued to improve, reflecting the Group's efforts in service quality and customer experience[26]. - The Group revamped its loyalty programme to improve customer retention, which has shown effectiveness in strengthening business performance[17]. - The Group is focusing on enhancing customer retention through strategies based on customer spending patterns[30]. Strategic Direction - The Group's future strategies focus on enhancing branding, customer focus, professionalism, and management optimisation for sustainable growth[21]. - The introduction of innovative aesthetic treatments and continuous service portfolio improvement are key strategies to meet market demands[47]. - The Group aims to enhance brand value and adopt prudent financial strategies to achieve sustainable growth in the medical aesthetics and wellness beauty industry[60]. - The Group plans to accelerate the introduction of innovative treatments and product portfolios to enhance brand influence and market penetration in response to improving local consumer conditions[118]. Financial Health - Cash flow remained healthy, and gearing ratios were kept at a low level, resulting in a stable financial structure[18]. - Cash and cash equivalents rose to HK$182.3 million as of March 31, 2025, compared to HK$119.8 million in 2024, indicating improved liquidity[95]. - Interest-bearing bank borrowings decreased to approximately HK$5.9 million in FY2025 from HK$12.5 million in FY2024, reflecting reduced debt levels[97]. - The gearing ratio improved to approximately 4.0% as of March 31, 2025, down from 9.1% in 2024, demonstrating a stronger capital structure[100]. Management and Governance - Ms. LAI Ka Yee Gigi has been leading the Group since 2009, focusing on the medical aesthetic service industry after her career in film and television[123]. - The Group has a strong management team with diverse backgrounds in marketing, public health, and creative industries, enhancing its strategic capabilities[125]. - The Company aims to become a renowned enterprise in non-surgical medical aesthetic and wellness beauty services, targeting the creation of value for shareholders[156]. - The Company has complied with all applicable code provisions of the Corporate Governance Code for the year ended 31 March 2025, with one exception regarding the separation of roles of chairman and chief executive officer[154][155]. - The Board is composed of 3 executive directors and 3 independent non-executive directors, complying with the Listing Rules regarding board composition[160]. - The Company maintains a system of internal controls and risk management procedures as part of its governance responsibilities[175]. Corporate Governance - The company is committed to high standards of corporate governance, having complied with applicable codes and principles[171]. - The Company has established a corporate governance function to review and monitor policies, including compliance with legal and regulatory requirements[186]. - The Company encourages Directors to participate in continuous professional development to enhance their knowledge and skills[182]. - The Board held four regular meetings during the year ended March 31, 2025, with full attendance from all Executive Directors[176]. - The Audit Committee, comprising three Independent Non-Executive Directors, held three meetings during the year, attended by the Company's external auditor[189].

Financial Performance - For the fiscal year ending March 31, 2025, the group's revenue was approximately HKD 403.15 million, a decrease of about HKD 91.11 million or 18.4% compared to HKD 494.26 million for the fiscal year ending March 31, 2024[3]. - The company reported a profit attributable to equity holders of approximately HKD 10.6 million for the fiscal year ending March 31, 2025, reversing from a loss of HKD 12.6 million for the fiscal year ending March 31, 2024[3]. - Basic earnings per share for the fiscal year ending March 31, 2025, was HKD 0.0265, compared to a basic loss per share of HKD 0.0315 for the previous year[3]. - The group reported a net loss of HKD 10,590,000 for the year, with no potential dilutive ordinary shares issued[24]. - The group reported revenue of HKD 403.2 million for the fiscal year 2025, a decrease of 18.4% compared to HKD 494.3 million in fiscal year 2024[29]. - The group incurred income tax expenses of HKD 12,427,000 in 2025, compared to HKD 836,000 in 2024[21]. - The company expects to report a profit attributable to shareholders of approximately HKD 10.6 million in FY2025, compared to a loss of HKD 12.6 million in FY2024[47]. Assets and Liabilities - Total non-current assets decreased to HKD 156.29 million in 2025 from HKD 196.88 million in 2024[5]. - Current assets increased to HKD 314.99 million in 2025 from HKD 282.56 million in 2024, with cash and cash equivalents rising to HKD 182.32 million from HKD 119.83 million[5]. - Total current liabilities decreased to HKD 263.85 million in 2025 from HKD 277.98 million in 2024[5]. - The company's total assets less current liabilities increased to HKD 207.43 million in 2025 from HKD 201.47 million in 2024[5]. - The company reported a net cash position of HKD 51.14 million in 2025, compared to HKD 4.59 million in 2024[5]. - Non-current assets total HKD 168,997,000 in 2025, an increase from HKD 128,839,000 in 2024[15]. - Total non-current liabilities amount to HKD 59,866,000 in 2025, down from HKD 64,703,000 in 2024, indicating a decrease of 7.1%[6]. Revenue Breakdown - Revenue from treatment services was approximately HKD 350.3 million, accounting for 86.9% of total revenue, a decrease of about HKD 24.2 million or 6.5% due to a relatively weak economic environment[37]. - Revenue from skincare products dropped significantly to HKD 52,804,000 in 2025 from HKD 119,641,000 in 2024, representing a decline of 55.9%[17]. - Revenue from Hong Kong for 2025 is expected to be HKD 400,318,000, down 11.2% from HKD 450,819,000 in 2024[15]. Operational Efficiency - The company is focusing on improving operational efficiency and exploring new market opportunities to drive future growth[4]. - Operating profit before interest, tax, and depreciation increased to HKD 58.6 million, up 84.9% from HKD 31.7 million in the previous fiscal year[29]. - Operating expenses were reduced by 24.5% year-on-year, significantly lowering the expense-to-revenue ratio[30]. - Employee costs decreased by approximately HKD 42.2 million or 23.0% to about HKD 141.6 million in fiscal year 2025, mainly due to the optimization of operational structure and systems[41]. - Property rental and related expenses are expected to decrease from approximately HKD 67.9 million in FY2024 to HKD 54.2 million in FY2025, a reduction of about HKD 13.7 million or 20.2% due to network optimization and better lease terms negotiations[42]. - Other expenses are expected to decrease from approximately HKD 159.6 million in FY2024 to HKD 100.1 million in FY2025, a reduction of about HKD 59.5 million or 37.3%[44]. Market and Strategic Focus - The company operates primarily in the medical beauty and lifestyle beauty services sector, focusing on Hong Kong and mainland China markets[13]. - The market for medical beauty and lifestyle beauty in Hong Kong is expected to continue growing, driven by increasing consumer demand and technological advancements[28]. - The company is focusing on innovation in medical beauty services and expanding its diverse customer base in prime commercial areas of Hong Kong[29]. - The skincare retail segment faced challenges but implemented multi-faceted strategies to optimize product mix and enhance customer experience[30]. - Customer satisfaction continued to improve, with a growing customer base reflecting the company's commitment to service quality and customer experience[30]. Governance and Compliance - The company has adopted the corporate governance code and has complied with all applicable provisions as of March 31, 2025, except for specific deviations noted[59]. - The board believes that the current structure, with the same individual serving as both Chairperson and CEO, is in the best interest of the company, thus accepting the deviation from the corporate governance code[60]. - The audit committee, consisting of three independent non-executive directors, has reviewed the consolidated financial statements for the year ending March 31, 2025[63]. - The auditors confirmed that the financial figures in the preliminary announcement are consistent with the draft consolidated financial statements for the year ending March 31, 2025[64]. Other Financial Information - The provision for restoration costs increased to HKD 11,056,000 in 2025 from HKD 8,800,000 in 2024, representing a rise of 25.5%[6]. - Deferred tax liabilities decreased to HKD 2,754,000 in 2025 from HKD 4,395,000 in 2024, a reduction of 37.3%[6]. - The company had outstanding interest-bearing bank borrowings of approximately HKD 5.9 million as of March 31, 2025, down from HKD 12.5 million in FY2024[51]. - The company has no supplier financing arrangements, thus recent accounting standard amendments do not impact its financial statements[12]. - No significant events occurred after the reporting period[62].

Financial Performance - Loss attributable to the owners of the Company was approximately HK$0.6 million for the six months ended 30 September 2024, a significant improvement from a loss of HK$13.1 million for the same period in 2023[8]. - Revenue for the six months ended 30 September 2024 was HK$200.1 million, down from HK$237.0 million in the previous year, representing a decrease of approximately 15.6%[10]. - The Company reported a profit before tax of HK$1.8 million for the six months ended 30 September 2024, compared to a loss before tax of HK$16.6 million for the same period in 2023[10]. - Total comprehensive loss for the period was HK$156,000, a notable reduction from HK$13.2 million in the prior year[10]. - Basic and diluted loss per share attributable to ordinary equity holders of the Company was HK(0.16) cents, compared to HK(3.26) cents for the same period in 2023[10]. - The company reported a loss for the period of HK$630,000 for the six months ended September 30, 2024, compared to a loss of HK$13,050,000 for the same period last year[21]. - The Group's profit before tax for the six months ended September 30, 2024, was a loss of HK$630,000, significantly improved from a loss of HK$13,050,000 in the same period of 2023[89]. - Total tax charge for the period was HK$2,393,000, compared to a tax credit of HK$3,584,000 in the previous year[83]. Revenue Breakdown - Revenue from contracts with customers for the six months ended September 30, 2024, was HK$200,076,000, a decrease of 15.6% compared to HK$237,010,000 for the same period in 2023[68]. - Revenue from Hong Kong was HK$195,040,000, down from HK$215,069,000, representing a decline of 9.3%[41]. - Revenue from the Chinese Mainland significantly decreased to HK$5,036,000 from HK$21,941,000, a decline of 77%[41]. - Treatment services generated revenue of HK$170,722,000, while skincare products revenue dropped to HK$29,336,000, down 51.7% from HK$60,631,000 in the previous year[68]. Cost Management - Staff costs decreased to HK$25.4 million from HK$27.0 million year-on-year, reflecting a reduction of approximately 5.8%[10]. - Property rentals and related expenses decreased to HK$74.2 million from HK$91.5 million, a reduction of approximately 18.9%[10]. - Finance costs decreased significantly to HK$51.4 million from HK$79.5 million, indicating a reduction of approximately 35.4%[10]. - Other expenses, net decreased by approximately HK$28.1 million or 35.3%, from approximately HK$79.5 million in the previous period to approximately HK$51.4 million in the current period[141]. - Cost of inventories and consumables amounted to approximately HK$25.4 million for the period under review, representing 12.7% of total revenue[134]. Asset and Liability Management - Total non-current assets decreased slightly to HK$195,688,000 as of September 30, 2024, from HK$196,881,000 as of March 31, 2024[14]. - Current assets totaled HK$272,981,000, a decrease from HK$282,562,000 as of March 31, 2024, primarily due to a reduction in trade receivables[14]. - Net current assets improved to HK$19,046,000 compared to HK$4,585,000 as of March 31, 2024, indicating better liquidity[14]. - Total current liabilities decreased to HK$253,935,000 from HK$277,977,000, reflecting a reduction in other payables and accruals[14]. - Non-current liabilities increased to HK$78,127,000 as of September 30, 2024, up from HK$64,703,000 as of March 31, 2024, mainly due to higher lease liabilities[17]. - Total equity remained stable at HK$136,607,000 as of September 30, 2024, compared to HK$136,763,000 as of March 31, 2024[17]. - Cash and cash equivalents increased to HK$128,561,000 from HK$119,829,000, indicating improved cash flow management[14]. - Cash and cash equivalents at the end of the period were HK$89,092,000, an increase from HK$77,329,000[26]. - The company reported a net increase in cash and cash equivalents of HK$13,278,000, contrasting with a decrease of HK$28,199,000 in the prior period[26]. - The Group's non-current assets as of September 30, 2024, totaled HK$164,461,000, a decrease from HK$168,997,000 as of March 31, 2024[60]. - Trade receivables as of September 30, 2024, amounted to HK$3,803,000, a significant decrease of 71.7% from HK$13,402,000 as of March 31, 2024[98][103]. - Trade payables totaled HK$9,189,000 as of September 30, 2024, a decrease from HK$10,561,000 as of March 31, 2024[107]. Employee and Management - The Group had a total of 242 employees, a decrease from 413 employees as of September 30, 2023[151]. - Key management personnel compensation for the six months ended September 30, 2024, totaled HK$4,847,000, slightly down from HK$4,996,000 in the same period of 2023[117]. - Employee costs for the six months ended September 30, 2024, were approximately HKD 74.2 million, down from approximately HKD 91.5 million for the same period in 2023[155]. Strategic Focus and Future Outlook - The Group plans to adopt a cautious and prudent operating strategy in the second half of the year, focusing on optimizing operational strategies and cost to maintain competitiveness[132]. - The Group remains committed to high-quality service delivery to strengthen customer confidence and loyalty to its brand[130]. - The Group's strategic focus will prioritize resources towards core businesses with competitive advantages to enhance overall profitability and shareholder value[132]. - The company plans to introduce new treatments and products to enhance brand visibility and market presence in response to evolving market demands[161]. - The group recognizes the structural transition in the consumer market and will continue to adopt cautious and prudent operating strategies[159]. - The group has implemented strategic measures to diversify revenue streams and reduce expenses, including optimizing its sales network and launching promotional activities[160]. Compliance and Governance - The company has confirmed compliance with the Model Code for Securities Transactions by Directors, with all directors affirming adherence to the required standards during the six months ended September 30, 2024[195]. - The company has adopted a non-competition undertaking to ensure compliance with relevant regulations[199]. - The Company aims to ensure that its business operations remain free from direct competition from its Controlling Shareholders[200]. - The non-competition undertakings are designed to protect the Company's market position and strategic interests[200]. - The Controlling Shareholders have committed to non-competition undertakings as per the deed dated December 19, 2016[200].

Financial Performance - For the six months ended September 30, 2024, the group's revenue was approximately HKD 200.08 million, a decrease of about HKD 36.93 million or 15.6% compared to HKD 237.01 million for the same period in 2023[1]. - The company reported a loss attributable to equity holders of approximately HKD 630,000, compared to a loss of HKD 13.31 million for the same period in 2023[1]. - Total comprehensive loss for the period amounted to HKD 156,000, compared to HKD 13.19 million in the previous period[4]. - Basic and diluted loss per share was HKD 0.16, compared to HKD 3.26 for the same period last year[4]. - The group reported a pre-tax profit of HKD 19,259 thousand for the six months ended September 30, 2024, compared to HKD 20,868 thousand for the same period in 2023, reflecting a decrease of 7.7%[23]. - The company recorded a revenue of HKD 201 million for the six months ended September 30, 2024, a decrease of 15.6% compared to HKD 237 million for the same period in 2023[37]. - The net loss for the current period was approximately HKD 630,000, significantly reduced from a net loss of HKD 13.1 million in the previous period[37]. - The group’s total tax expense for the period was HKD 2,393 thousand, compared to a tax benefit of HKD 3,584 thousand in the same period last year[26]. Revenue Breakdown - Revenue for the six months ended September 30, 2024, was HKD 200,076 thousand, a decrease of 15.6% compared to HKD 237,010 thousand for the same period in 2023[17]. - Revenue from non-surgical medical beauty services was HKD 170,722 thousand, down from HKD 176,335 thousand year-on-year, representing a decline of 3.5%[22]. - Revenue from skincare products significantly decreased to HKD 29,336 thousand from HKD 60,631 thousand, a drop of 51.6%[22]. - The revenue from mainland China dropped significantly to HKD 5,036 thousand from HKD 21,941 thousand, a decline of 77.0%[17]. Assets and Liabilities - Non-current assets as of September 30, 2024, totaled HKD 195.69 million, slightly down from HKD 196.88 million as of March 31, 2024[7]. - Current assets amounted to HKD 272.98 million, a decrease from HKD 282.56 million as of March 31, 2024[7]. - Current liabilities were HKD 253.94 million, down from HKD 277.98 million as of March 31, 2024[8]. - The total equity value as of September 30, 2024, was HKD 136.61 million, unchanged from HKD 136.76 million as of March 31, 2024[9]. - Trade receivables as of September 30, 2024, amounted to HKD 3,803,000, down from HKD 13,402,000 as of March 31, 2024[33]. - Trade payables as of September 30, 2024, totaled HKD 9,189,000, compared to HKD 10,561,000 as of March 31, 2024[34]. - The company's lease liabilities amounted to approximately HKD 107 million as of September 30, 2024[55]. - The debt-to-equity ratio was approximately 6.7% as of September 30, 2024, down from 9.1% on March 31, 2024[60]. Operational Efficiency - The company has implemented targeted advertising strategies and improved internal management systems to enhance operational efficiency and reduce costs[36]. - Other net expenses decreased by approximately HKD 28.1 million or 35.3% to about HKD 51.4 million, attributed to improved operational efficiency and effective cost control[48]. - Employee costs decreased by approximately HKD 17.3 million or 18.9% to about HKD 74.2 million, with the number of employees reduced from 413 to 242[45]. - Property rental and related expenses decreased by approximately HKD 6 million or 17.2% to about HKD 28.9 million, primarily due to the closure of retail stores[46]. Corporate Governance - The company has adhered to all applicable corporate governance rules during the six-month period ended September 30, 2024, with one exception regarding the separation of the roles of Chairman and CEO[71]. - The Audit Committee, consisting of three independent non-executive directors, has reviewed the financial information for the six months ended September 30, 2024[74]. - The company believes that maintaining high standards of corporate governance is essential for managing business risks and enhancing transparency[71]. Future Outlook - The company plans to introduce new therapies and products to increase brand awareness and market coverage, responding to changing market demands[67]. - The company has adopted a cautious and prudent operational strategy to adapt to structural changes in the consumer market[66]. - The economic environment remains challenging, impacting market sentiment and business operations[36]. - The company has maintained a low debt ratio over the years, ensuring a stable financial position despite a relatively high interest rate environment[66]. Dividends and Shareholder Returns - The board of directors did not declare an interim dividend for the six months ended September 30, 2024, consistent with the previous year[1]. - The group did not declare any interim dividend for the six months ended September 30, 2024, consistent with the same period in 2023[27]. - The company has not engaged in any purchases, sales, or redemptions of its own shares during the six-month period ended September 30, 2024[68]. Employment and Workforce - As of September 30, 2024, the group employed 242 employees, a decrease from 413 employees as of September 30, 2023[64]. - Employee costs for the six months ended September 30, 2024, were approximately HKD 74.2 million, down from HKD 91.5 million for the same period in 2023[64]. Business Operations - The company operates three CosMax+ medical beauty centers in Hong Kong, enhancing its customer base and service offerings[38]. - The XOVĒ skincare product line, developed by a Swiss research team, is marketed through various platforms, including retail stores and e-commerce, despite a challenging retail environment[40].